| Code | CSB-RA751251MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Bapotulimab, targeting immunoglobulin-like domain-containing receptor 2 (ILDR2). ILDR2 is a cell surface protein that functions as a receptor involved in cellular adhesion and immune regulation processes. This protein has emerged as a significant target in oncology research, particularly in the context of tumor-associated macrophages and the immunosuppressive tumor microenvironment. ILDR2 expression has been implicated in various malignancies where it may contribute to immune evasion mechanisms and tumor progression.
Bapotulimab represents an investigational therapeutic antibody designed to modulate immune responses in the tumor microenvironment by targeting ILDR2-expressing cells. This biosimilar antibody provides researchers with a valuable tool for investigating ILDR2 biology, exploring its role in cancer immunology, and studying potential immunotherapeutic approaches. The antibody enables detailed examination of ILDR2-mediated signaling pathways, immune cell interactions, and its contribution to tumor immune escape mechanisms in preclinical models.
There are currently no reviews for this product.